RANKL blockade prevents and treats aggressive osteosarcomas-Reference-Cited by-同舟云学术

RANKL blockade prevents and treats aggressive osteosarcomas

Published:2015-12-09 Issue:317 Volume:7 Page:
ISSN:1946-6234
Container-title:Science Translational Medicine
language:en
Short-container-title:Sci. Transl. Med.

Author:

Chen Yan¹,Di Grappa Marco A.¹,Molyneux Sam D.¹,McKee Trevor D.²,Waterhouse Paul¹,Penninger Josef M.³,Khokha Rama¹

Affiliation:

1. Princess Margaret Cancer Centre/Ontario Cancer Institute, University Health Network, 101 College Street, Toronto, Ontario M5G 1L7, Canada.

2. Spatio-Temporal Targeting and Amplification of Radiation Response (STTARR) Program, University Health Network, 101 College Street, Toronto, Ontario M5G 1L7, Canada.

3. Institute of Molecular Biotechnology of the Austrian Academy of Sciences (IMBA), Dr. Bohr-Gasse 3, 1030 Vienna, Austria.

Abstract

Denosumab, an antibody targeting RANKL, is effective against osteosarcoma in mouse models.

Funder

Canadian Institutes of Health Research (CIHR)

Ontario Institute for Cancer Research (OICR)

Global Leadership Round in Genomics

Publisher

American Association for the Advancement of Science (AAAS)

Subject

General Medicine

Reference55 articles.

1. A review of clinical and molecular prognostic factors in osteosarcoma

2. Biology and Therapeutic Advances for Pediatric Osteosarcoma

3. Cyclic Adenosine Monophosphate/Protein Kinase A Mediates Parathyroid Hormone/Parathyroid Hormone-Related Protein Receptor Regulation of Osteoclastogenesis and Expression of RANKL and Osteoprotegerin mRNAs by Marrow Stromal Cells

4. Conditionally Immortalized Murine Bone Marrow Stromal Cells Mediate Parathyroid Hormone-Dependent Osteoclastogenesisin Vitro1

5. Osteoclast differentiation and activation

Cited by 72 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Identification of hub genes related to metastasis and prognosis of osteosarcoma and establishment of a prognostic model with bioinformatic methods;Medicine;2024-06-07

2. Amicis Omnia Sunt Communia: NF-κB Inhibition as an Alternative to Overcome Osteosarcoma Heterogeneity;Pharmaceuticals;2024-06-05

3. From biology to personalized medicine: Recent knowledge in osteosarcoma;European Journal of Medical Genetics;2024-06

4. Engineering small-molecule and protein drugs for targeting bone tumors;Molecular Therapy;2024-05

5. POLE2 promotes osteosarcoma progression by enhancing the stability of CD44;Cell Death Discovery;2024-04-16